Sangamo price target raised to $5 from $3 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Sangamo to $5 from $3 and keeps a Buy rating on the shares. The higher target better reflects the potential upside from the Sifter platform, the analyst tells investors in a research note. The analyst believes the novel capsid discovery may unlock significant value for Sangamo’s internal neurology programs with “best-in-class potential,” and supports its new core strategy focused on the development of neurogenetic medicines.